L. Shargel, S. Wu-pong, and A. Yu, Applied Biopharmaceutics & Pharmacokinetics, 2005.

I. Younis, S. Malone, H. Friedman, L. Schaaf, and W. Petros, Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma, Cancer Chemotherapy and Pharmacology, vol.8, issue.3
DOI : 10.1007/s00280-008-0769-8

X. Panhard, C. Goujard, M. Legrand, A. Taburet, B. Diquet et al., Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART, British Journal of Clinical Pharmacology, vol.46, issue.4, pp.390-403, 2005.
DOI : 10.1002/sim.1619

Y. Feng, B. Pollock, K. Coley, S. Marder, D. Miller et al., Population 555 pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study, Br J Clin Pharmacol, vol.66, pp.629-639, 2008.

M. Lindstrom and D. Bates, Nonlinear Mixed Effects Models for Repeated Measures Data, Biometrics, vol.46, issue.3, pp.673-687, 1990.
DOI : 10.2307/2532087

S. Beal, L. Sheiner, A. Boeckmann, R. Bauer, . Nonmem et al., Ellicott 560, Guides, 1989.

P. Girard and F. Mentré, A comparison of estimation methods in nonlinear mixed effects models using a blind analysis. Pamplona, Spain: 14th Population Approach Group in Europe Available from: http://www.page-meeting, 2005.

J. Bertrand, E. Comets, and F. Mentré, Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters, Journal of Biopharmaceutical Statistics, vol.5, issue.6, pp.1084-102, 2008.
DOI : 10.1111/j.1525-1438.2006.00593.x
URL : https://hal.archives-ouvertes.fr/inserm-00339183